日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases.

PRL3-zumab 作为新生血管性眼病的抗血管生成疗法

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-59929-2
Ang Koon Hwee, Thura Min, Tan Queenie Shu Woon, Gupta Abhishek, Kuan Kam Yew, Li Jie, Chia Pei Ling, Qiu Beiying, Hong Jimmy Ming, Guo Ke, Wang Xiaomeng, Su Xinyi, Zeng Qi
心血管
血管生成
发表日期：2025
文献求助 收藏

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy

PRL3-zumab 范式：一项非常规癌症免疫疗法的多中心、单剂量水平 II 期篮式临床试验设计

期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102120
Park, David J; Thura, Min; Chiu, Vi K; Vicuna, Brian; Ang, Koon Hwee; Sanchez, Blanca; Chia, Pei Ling; Kuan, Kam Yew; Li, Jie; Zhang, Ke; Zheng, Wei Hui; Hsien Ng, Matthew Chau; Zeng, Qi
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types

PRL3作为多种癌症类型新型癌症免疫疗法的治疗靶点

期刊:Theranostics
影响因子:13.3
doi:10.7150/thno.79265
Chia, Pei Ling; Ang, Koon Hwee; Thura, Min; Zeng, Qi
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2023
文献求助 收藏

Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse

作者更正：PRL3诱导多倍体巨型癌细胞，PRL3-zumab可消除这些细胞以减少肿瘤复发

期刊:Communications Biology
影响因子:5.1
doi:10.1038/s42003-021-02812-9
Thura, Min; Ye, Zu; Al-Aidaroos, Abdul Qader; Xiong, Qiancheng; Ong, Jun Yi; Gupta, Abhishek; Li, Jie; Guo, Ke; Ang, Koon Hwee; Zeng, Qi
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏